Treatment advances in gout.

Gout / drug therapy Gout Suppressants / therapeutic use Humans Uric Acid / therapeutic use
Flares Gout Treatment Urate lowering

Journal

Best practice & research. Clinical rheumatology
ISSN: 1532-1770
Titre abrégé: Best Pract Res Clin Rheumatol
Pays: Netherlands
ID NLM: 101121149

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 11 11 2021
medline: 11 1 2022
entrez: 10 11 2021
Statut: ppublish

Résumé

The purpose of gout treatment is to alleviate symptoms of flares, prevent flares from recurring by lowering serum urate, and minimize structural joint damage and functional impairment. In recent years, several new medications to treat gout have been developed, and novel agents continue to be investigated, in addition to several long-established treatments. Although a number of effective therapies are available, optimal management and outcomes are frequently not achieved due to physician under prescribing of urate-lowering therapy (ULT) and poor adherence with therapy when it is prescribed. This article reviews recent developments in the management of gout with reference to recently published clinical guidelines, outlines some important questions regarding the safety and efficacy of particular agents, and remaining gaps in our knowledge about the most effective strategies for using currently available treatments.

Identifiants

DOI: 10.1016/j.berh.2021.101719 PMID: 34756509
pubmed: 34756509
pii: S1521-6942(21)00061-9
doi: 10.1016/j.berh.2021.101719
pii:
doi:

Substances chimiques

Gout Suppressants 0
Uric Acid 268B43MJ25

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101719

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None to declare.

Auteurs

Lisa K Stamp (LK)

Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch, 8140, New Zealand. Electronic address: Lisa.Stamp@cdhb.health.nz.

Hamish Farquhar (H)

Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch, 8140, New Zealand. Electronic address: Hamish.Farquhar@cdhb.health.nz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Erreurs innées du métabolisme › Erreurs innées du métabolisme de la purine et de la pyrimidine › Goutte › Treatment advances in gout.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Antigoutteux › Treatment advances in gout.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Treatment advances in gout.
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Purines › Purinones › Xanthines › Acide urique › Treatment advances in gout.